공시 • Apr 24
Ventripoint Diagnostics Ltd. has filed a Follow-on Equity Offering. Ventripoint Diagnostics Ltd. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 555,699 공시 • Mar 17
Ventripoint Diagnostics Ltd., Annual General Meeting, May 27, 2026 Ventripoint Diagnostics Ltd., Annual General Meeting, May 27, 2026. Location: ontario, toronto Canada 공시 • Jan 19
Ventripoint Diagnostics Ltd. announced that it has received CAD 1.009772 million in funding On January 19, 2026, Ventripoint Diagnostics Ltd. closed the transaction. The company issued 10,097,720 units at a price of CAD 0.10 per unit for gross proceeds of CAD 1,009,772. Directors and Officers of the company (insiders) invested an aggregate of CAD 139,340, which was 13.8% of the total proceeds. The corporation has paid cash finder’s fees of CAD 15,600 and issued common share purchase warrants (“finder’s warrants”) to purchase an aggregate of 156,000 shares of the company. Each finder’s warrant will be exercisable into one common share at an exercise price of CAD 0.13 per common share for a period of 24 months from the closing of the offering. 공시 • Jan 01
Ventripoint Diagnostics Ltd. announced that it expects to receive CAD 0.5 million in funding Ventripoint Diagnostics Ltd. announced a non-brokered private placement of up to 5,000,000 units at an issue price of CAD 0.10 per unit for gross proceeds of CAD 500,000 on December 31, 2025. Each unit will comprise one common share of the corporation and one common share purchase warrant. Each whole warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.13 for a period of 24 months from the closing of the offering. The corporation may pay cash finder's fee and issue common share purchase warrants of up to CAD 0.08 of the gross proceeds of the offering. Each finder's warrant will be exercisable into one common share at an exercise price of CAD 0.13 per common share for a period of 24 months from the closing of the offering. All securities issued and issuable pursuant to the offering will be subject to a hold period of four months plus one day from the date of closing of the offering. The offering is subject to approval by the exchange. 공시 • Dec 12
Ventripoint Diagnostics Ltd. Unveils Global Model for A.I.- Enhanced Heart Care Through Partnership with the Nisga'a Valley Health Authority Ventripoint Diagnostics Ltd. announced a transformative partnership with Nisga'a Valley Health Authority (NVHA) that is the next step towards forming a new model for delivering accessible, high-quality heart care powered by artificial intelligence. The new model follows a "hub-and-spoke" design, where a central hub with advanced cardiac capabilities provides support to connected sites in smaller, remote, and Indigenous communities. Local healthcare providers can acquire, enhance and read ultrasound scans using VMS+™? and transmit them digitally as needed to specialists at the hub for rapid interpretation and consultation. The Nisga'a Valley health Authority will serve as the first remote site in this expanding network, and will be linked to a regional centre with tertiary and quaternary care capabilities. Future phases are intended to include: Additional First Nations communities in British Columbia and all of Canada. Arctic regions across the country. Rural and northern communities worldwide. Communities in the Amazon, Africa, India, and other regions where MRI access is limited. This expected results of the model are simple yet profound: delivering advanced cardiac imaging directly to patients - Indigenous and non-Ind Indigenous - without the need for long-distance travel, high costs, or extended wait times. At the core of this model is Ventripoint's VMS+™? system, which delivers MRI-level heart measurement accuracy by transforming standard 2D echocardiograms into 3D volumetric images. This technology enables precise cardiac assessments to be performed at the point of care, reducing costs and eliminating the need for time-consuming MRI scans. The system is already being used to support diagnosis and monitoring of indications such as congenital heart disease, post-surgical recovery, chemotherapy-related cardiac complications, pulmonary hypertension, heart failure, and valve dysfunction. Ventripoint plans to expand this model throughout Canada and internationally, advancing the goal of universal access to affordable, accurate cardiac diagnostics. 공시 • Dec 04
Ventripoint Diagnostics Ltd. Announces Chief Financial Officer Changes Ventripoint Diagnostics Ltd. announced the appointment of David Swetlow, CPA, CA, iGP as Chief Financial Officer (CFO), effective immediately. This appointment represents an important step in strengthening Ventripoints leadership team as the Company embarks on its new commercial strategic vision and transitions into its growth phase. Mr. Swetlow brings extensive senior management, financial and public company leadership experience from various roles across high-growth medical technology and innovative life science companies, including Sernova, Ondine, Protox, HealthPricer, One Person Health, QLT and Xillix, with a track record of building and executing robust capital markets strategies; company scale up, product launch and commercialization strategies success; driving and evolving financial systems, reporting, and operational performance for next stage growth; strategic relationship management; and enhancing corporate governance. His broad expertise will be instrumental to positioning VPT to achieve the next stage of VMS+ platform market adoption success and expansion abroad. This is a pivotal moment for Ventripoint, said Hugh MacNaught, President &CEO of Ventripoint Diagnostics. Davids leadership will play a vital role as we execute on a refreshed commercial strategy designed to scale our technology and platform, strengthen our global partnerships, and position the company for new markets and revenue growth. As Ventripoint moves into this next stage, the Company also extends its appreciation to Jimmy Jeon, who has resigned as CFO and Marelli Services for their valuable support to date. Their contributions have helped provide stability and continuity through a period of important transition. As CFO, Mr. Swetlow will oversee financial strategy, capital markets, financial reporting and operations, working closely with the executive team and Board of Directors as VPT advances commercialization efforts in the U.S., Canada, Europe, the UK, and other priority markets. 